Donald E. Bobo, Jr. Sells 9,500 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the transaction, the vice president now owns 47,206 shares of the company’s stock, valued at $3,295,450.86. The trade was a 16.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Edwards Lifesciences Trading Up 0.7 %

NYSE EW traded up $0.46 during trading on Monday, hitting $69.86. 3,576,193 shares of the company’s stock traded hands, compared to its average volume of 4,908,913. The firm has a market cap of $41.07 billion, a P/E ratio of 10.02, a PEG ratio of 4.82 and a beta of 1.15. The stock has a fifty day moving average of $71.32 and a two-hundred day moving average of $70.74. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EW. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Truist Financial dropped their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $78.55.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. raised its stake in shares of Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 273 shares during the last quarter. Nordea Investment Management AB increased its holdings in Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its position in Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $4,845,000. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.